Highest-materiality recent filing
AIxCrypto enters $50M common share purchase agreement with Gold King Arthur Holding
Agreement allows AIxCrypto to sell up to $50M in common shares to Gold King Arthur via VWAP purchases over 24 months.
AIxCrypto Holdings announces executive resignations, appointments, and wind-down of biotech segment
Co-CEO Kevin Richardson II and director resigned effective May 21, 2026, with no disagreement disclosed.
AIxCrypto pre-revenue in Q1; cash & digital assets $12.4M, $10M prepaid in Faraday
Zero revenue; operating expenses $4.3M vs $2.7M a year ago, driven by higher G&A.
AIxCrypto amends investment agreement with GKA; expands FFAI scope, increases subscription to $12M
Entrusted investment agreement amended to include FFAI preferred stock and debt instruments.
Completed $41M PIPE with Faraday Future (FFAI) as lead investor; rebranded from Qualigen to AIxCrypto in November 2025.
Yueting Jia appointed Chief Advisor; $500K annual fee, $300K one-time engagement fee, plus annual RSU/PSU grants of $1.5M each.
AIxCrypto enters $10M FFAI investment, $100K/month consulting, Sei collaboration
Consulting agreement with FF Global Partners for $100K/month plus up to $1M quarterly performance bonuses.
AIxCrypto enters non-binding term sheet to invest $10M in Faraday Future for tokenization strategy
Non-binding term sheet to purchase $10M tranche of Faraday Future (NASDAQ: FFAI) common stock.
AIxCrypto (formerly Qualigen) rebrands to AI Web3; plans $5M tokenized FFAI stock purchase
Company renamed to AIxCrypto Holdings, Inc., trading under new ticker AIXC on Nasdaq.
Nasdaq cites AIxCrypto for failure to get shareholder nod on PIPE; now compliant but monitored
PIPE financing closed Sept 29, 2025 raised $41M; sold 337,432 common shares at $2.246 and 17,783 Series B preferred at $1,000/share.
Koti Meka appointed Executive Director Nov 17, 2025; he also serves as CFO of the Company and Faraday Future.
Stockholders approved private placement of 337,432 common shares and 39,943 Series B convertible preferred shares.
Qualigen appoints new Co-CEO, CFO, three directors; auditor switches to MGO
Withum resigned as auditor on Oct 1, 2025; MGO appointed Oct 3, 2025 for FY2025 audit and interim reviews.
Qualigen closes $41M PIPE led by Faraday Future, pivots to crypto business as CXC10
Faraday Future invested $30M for ~55% pro forma beneficial ownership; YT Jia invested $4M with 2-yr lockup.
Qualigen Therapeutics enters $41M PIPE led by Faraday Future; plans crypto pivot and rebrand
Faraday Future leads $30M investment at $2.246/share for ~55% beneficial ownership; YT Jia personally invests $4M.
Qualigen gets final Nasdaq extension to prove equity compliance by Nov 15 after negative equity
Nasdaq Panel granted final exception to demonstrate compliance with $2.5M equity rule by Nov 15, 2025; no further extensions.
Qualigen restructures $4.45M Marizyme note, secures assets, pro forma equity positive
Amended Note principal $4,451,462 with 18% interest, due Aug 21, 2026; includes $216K new advance.
Qualigen closes $4.5M private placement of Series A-3 Preferred; conversion price $2.80
Issued 4,500 Series A-3 Preferred shares at $1,000 each for $4.5M gross proceeds.
Received Nasdaq notice on July 23, 2025 for failing to meet $2.5M stockholders' equity requirement.
Qualigen granted patents for QN-302 covering 25 countries through 2040
Patents for QN-302 granted in over 20 European countries plus India, China, and Russia.
Qualigen receives Nasdaq deficiency notice for late Q1 10-Q; delisting hearing set
Nasdaq notified Qualigen on May 19, 2025 of failure to timely file Form 10-Q for quarter ended March 31, 2025.
Qualigen gets Nasdaq delisting notice for late 10-K; faces suspension May 5 if no appeal
Received April 24 notice of non-compliance with Nasdaq Listing Rule 5250(c) due to delayed 2024 Form 10-K.
Qualigen raises $5.1M in Series A-2 Preferred private placement; exchanges $1.1M notes
Issued 5,100 shares of Series A-2 Preferred at $1,000/share for $5.1M aggregate proceeds.
Qualigen Therapeutics effects 1-for-50 reverse stock split to regain Nasdaq compliance
Reverse stock split at 1:50 ratio effective 12:01 a.m. ET on November 5, 2024.
Qualigen Therapeutics announces 1-for-50 reverse stock split to regain Nasdaq compliance
Effective Nov 5, 2024, at 12:01 a.m. ET; trading on split-adjusted basis from market open.
All five director nominees elected, each receiving over 14.3 million votes.
Qualigen CEO and CFO resign over disagreements; Board appoints interim CEO/CFO and President
Michael Poirier (CEO/Chairman) and Christopher Lotz (CFO) resigned immediately on Sep 23, 2024, citing disagreements over company's future direction.
Qualigen Therapeutics receives Nasdaq extension to continue listing through November 19, 2024
Received Nasdaq Hearings Panel notice on Sept 11, 2024 granting extension for continued listing.
Qualigen closes $3.47M public offering of shares and warrants at $0.13
Offering of 14,724,058 shares at $0.13/share plus pre-funded warrants for 11,972,754 shares at $0.129.
Qualigen Therapeutics prices $3.46M public offering of common stock and pre-funded warrants
Offering: 14,724,058 shares at $0.13 each and pre-funded warrants for 11,972,754 shares at $0.129 per warrant.
Qualigen gets Nasdaq extension to Oct 31 to regain bid price and equity compliance
Nasdaq Hearings Panel granted extension until October 31, 2024 to regain compliance.
Qualigen Therapeutics Advances $1.25 Million to Marizyme via Promissory Note at 18% Interest
Qualigen advanced $1,250,000 to Marizyme, Inc. on July 15, 2024, under a demand promissory note dated July 12, 2024.
Qualigen issues $2M senior note at 18%, replaces four directors
Issued $2M senior note to Corbo Capital Inc., due July 8, 2025, with 18% annual interest, unsecured, non-convertible.
Qualigen issues $2M senior note at 18% interest; board reshuffled; convertible debenture converted
Issued $2M senior note at 18% annual interest, matures July 8, 2025, with prepayment from future financings.
Qualigen receives Nasdaq delisting notice for bid price, late filing, and equity shortfall
Closing bid price below $1.00 for 30+ consecutive business days triggers non-compliance with Minimum Bid Price Requirement.
Issued $1.1M 8% convertible debenture and warrant to Yi Hua Chen upon exercise of Alpha option for $1M cash.
On May 21, 2026, the Board appointed Jie (Jay) Sheng, current independent director of the Company, as President, and as Chief Financial Officer, effective June 21, 2026.
On May 21, 2026, Kevin Richardson II notified AIxCrypto Holdings, Inc.'s (the "Company") board of directors (the "Board") of his resignation from the positions of Co-Chief Executive Officer and director of the Company, effective immediately.
Koti Meka resigned from his positions as Chief Financial Officer and director of the Company. Mr. Meka's resignation as director is effective immediately, and his resignation as Chief Financial Officer is effective June 20, 2026.
On May 21, 2026, Campbell Becher resigned from his position as President of the Company, effective immediately.
Koti Meka resigned from his positions as Chief Financial Officer and director of the Company. Mr. Meka's resignation as director is effective immediately, and his resignation as Chief Financial Officer is effective June 20, 2026.
On May 21, 2026, Kevin Richardson II notified AIxCrypto Holdings, Inc.'s (the "Company") board of directors (the "Board") of his resignation from the positions of Co-Chief Executive Officer and director of the Company, effective immediately.
On May 21, 2026, the Board appointed Jerry Wang to serve as a director of the Company, effective immediately.
On November 7, 2024, the Board of Directors (the “Board”) appointed Graydon Bensler as an independent member of the Board, effective immediately
On October 8, 2024, the Board of Directors (the “Board”) appointed Braeden Lichti as an independent member of the Board, effective immediately, and approved the Director Agreement, attached hereto as Exhibit 10.1.
On October 3, 2024, Mr. Matt Korenberg, independent member and chairman of the audit committee of the board of directors (the “Board”) of Qualigen Therapeutics, Inc. (the “Company”), tendered his resignation from all positions held with the Company, with such resignation becoming effective immediately.
Mr. Christopher Lotz, Chief Financial Officer of the Company, also tendered his resignation from all positions held with the Company, with such resignation becoming effective immediately.
the board of directors (the “Board”) appointed Campbell Becher as President of the Company, effective immediately.
Max materiality 0.90 · Median 0.68 · Most common event other_material